Bio-Rad Laboratories, Inc. Share Price NYSE
Stocks
BIO.B
US0905721082
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 334.30 USD | +8.06% |
|
0.00% | -0.43% |
| 01/07 | Activist investors make bigger push for campaigns in H1, seek more M&A | RE |
| 03/06 | Bio-Rad Laboratories, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 08:45 AM |
| Market Cap | 862.89Cr 750.11Cr 698.19Cr 641.02Cr 1.21TCr 82TCr 1.23TCr 8.23TCr 3.23TCr 41TCr 3.24TCr 3.17TCr 1,37500Cr | P/E 2026 * |
39.1x | P/E 2027 * | 38.2x |
|---|---|---|---|---|---|
| Enterprise Value | 787.98Cr 684.99Cr 637.58Cr 585.38Cr 1.11TCr 75TCr 1.12TCr 7.52TCr 2.95TCr 37TCr 2.96TCr 2.89TCr 1,25600Cr | EV / Sales 2026 * |
3.07x | EV / Sales 2027 * | 2.91x |
| Free-Float |
60.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Bio-Rad Laboratories, Inc.
| 1 day | +3.64% | ||
| 1 month | +4.35% | ||
| 3 months | +3.31% | ||
| 6 months | +4.85% | ||
| Current year | -0.43% |
| 1 month | 293.37 |  | 309.37 |
| Current year | 244.54 | | 312.75 |
| 1 year | 244.54 | | 321.12 |
| 3 years | 0 | | 373.78 |
| 5 years | 0 | | 818.6 |
| 10 years | 0 | | 818.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 76 | 01/01/2003 |
| President | 61 | 09/09/2024 | |
Roop Lakkaraju
DFI | Director of Finance/CFO | 55 | 15/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CHM | Chairman | 76 | 01/01/2012 |
Jeffrey Edwards
BRD | Director/Board Member | 73 | 25/04/2017 |
Gregory Hinckley
BRD | Director/Board Member | 79 | 25/04/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.06% | 0.00% | - | - | 862.89Cr | |
| +1.35% | +2.56% | -16.96% | -2.69% | 18TCr | |
| +0.81% | +2.62% | -4.42% | -0.08% | 11TCr | |
| -0.68% | +0.47% | +7.97% | +62.64% | 6.06TCr | |
| +2.37% | +2.16% | +39.83% | +55.40% | 5.18TCr | |
| +1.60% | +5.92% | -6.10% | -40.04% | 4.56TCr | |
| +3.48% | +1.37% | - | - | 3.32TCr | |
| +2.54% | +16.65% | +5.26% | -32.60% | 3.15TCr | |
| +1.68% | +3.89% | +42.51% | -7.99% | 2.4TCr | |
| +1.58% | +6.69% | +0.67% | +0.26% | 2.23TCr | |
| Average | +0.54% | +3.05% | +8.60% | +4.36% | 6.24TCr | |
| Weighted average by Cap. | +0.33% | +2.06% | -0.22% | +5.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 256.73Cr 223.17Cr 207.73Cr 190.72Cr 360.15Cr 25TCr 365.73Cr 2.45TCr 960.98Cr 12TCr 964.16Cr 942.98Cr 41TCr | 263.49Cr 229.05Cr 213.2Cr 195.74Cr 369.64Cr 25TCr 375.37Cr 2.51TCr 986.29Cr 13TCr 989.56Cr 967.82Cr 42TCr |
| Net income | 22Cr 20Cr 18Cr 17Cr 32Cr 2.15TCr 32Cr 214.6Cr 84Cr 1.07TCr 85Cr 83Cr 3.59TCr | 23Cr 20Cr 19Cr 17Cr 32Cr 2.2TCr 33Cr 219.36Cr 86Cr 1.09TCr 86Cr 84Cr 3.67TCr |
| Net Debt | -75Cr -65Cr -61Cr -56Cr -105.08Cr -7.15TCr -106.7Cr -714.38Cr -280.37Cr -3.56TCr -281.3Cr -275.12Cr -12TCr | -97Cr -84Cr -78Cr -72Cr -135.44Cr -9.22TCr -137.53Cr -920.77Cr -361.38Cr -4.59TCr -362.57Cr -354.61Cr -15TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/26/14 | $309.37 | +3.64% | 75 |
| 31/26/31 | $0.000000 | - | 6 |
| 30/26/30 | $0.000000 | - | 20 |
| 29/26/29 | $0.000000 | - | 8 |
| 28/26/28 | $0.000000 | - | 13 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIO Stock
- BIO.B Stock
Select your edition
All financial news and data tailored to specific country editions
